Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00398372
Status
Completed

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphomas: Non-Hodgkin
  • Lymphomas: Non-Hodgkin Cutaneous Lymphoma
  • Lymphomas: Non-Hodgkin Diffuse Large B-Cell
  • Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
  • Lymphomas: Non-Hodgkin Mantle Cell
  • Lymphomas: Non-Hodgkin Marginal Zone
  • Lymphomas: Non-Hodgkin Peripheral T-Cell
  • Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Key Dates

Start date
Nov 30, 2000
Status verified
Jul 2010
Primary completion
Jun 30, 2007
Completion
Sep 30, 2009

Study Design

Enrollment
500 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP

Primary Outcome Measure

To characterize the molecular and cell biology of the tumor cells in lymphoma. [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies